Alliance Global Partners analyst Scott Henry lowered the firm’s price target on Vivos Therapeutics (VVOS) to $6 from $8.25 and keeps a Buy rating on the shares after the company reported Q3 earnings with results that were at the lower end of expectations. Results will take time to improve given the business model shift from dentists to sleep specialists, notes the firm, which expects “flattish results” in Q4 and lowered its revenue forecast for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VVOS: